Skip to main content
Equibles
PCSA logo

PCSA · Processa Pharmaceuticals, Inc. · Metrics

Track PCSA — free

Use PCSA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PCSA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.03 +0.04 (+2.01%)
Rebalance outlook locked
Going-concern doubt — cleared Aug 14, 2026

The latest filing states the doubt was alleviated.

“Following our acquisition of Vidya and closing of the related $200 million gross private placement (from which we received net proceeds of $183.3 million) on July 30, 2026, we believe our cash and cash equivalents will be sufficient to satisfy our cash requirements over the next 12 months and beyond. This represents a material change from what we reported in our 2025 Form 10-K that disclosed substantial doubt of our ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$5.56M
Shares
2.79M

PCSA metrics

44 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.99
Market cap
$5.56M

Price action

20 metrics
Price change (1W)
+5.4%
Price change (30D)
-17.2%
Price change (3M)
+6.1%
Price change (6M)
-26.0%
Price change (YTD)
-25.0%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
121.4%
Annualized volatility (3M)
122.8%
Beta
1.8
RSI (14D)
48.8
Price vs SMA 50
-3.0%
Price vs SMA 200
—
Avg volume (3M)
242,227
Relative volume
0.2
Average dollar volume
$506,548

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
2.79M

Valuation

12 metrics
P / E (TTM)
2.2
Trailing earnings · reciprocal yield 46.3%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-241.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2023-03-31

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
−$20,245
Operating profit (TTM)
−$12.86M
Net income (TTM)
−$13.44M
Trailing 12 months
Diluted EPS (TTM)
$1.00
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.17

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+337.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-649.3%
Debt / equity
—
Current ratio
0.9
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$196,325
Total assets
$2.07M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$11.97M
Capital expenditures (TTM)
—
R&D (TTM)
$6.23M
SG&A (TTM)
$1.37M
Stock compensation (TTM)
$614,656
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
12
13F filer change QoQ
+2
Institutional ownership
9.1%

Short interest

3 metrics
Short interest
2.4%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
37 / 100

Insider activity

2 metrics
Net insider buying (90D)
$50,595
Insider-sentiment score
90 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1533743 CUSIP 74275C403 13F (30d) 12 filings 12 filers Visit website Investor relations